ALK-Abelló Launches GRAZAX on the First Market

ALK-Abelló A/S has launched its tablet-based vaccine against grass pollen allergy, GRAZAX, in Germany. GRAZAX is the first allergy tablet to address the underlying cause of grass pollen allergy and not just the symptoms.

GRAZAX will subsequently be introduced in other European markets, beginning with countries where ALK-Abelló has affiliates. ALK-Abelló's efforts in these major markets will focus on serving physicians who work extensively in the field of allergy. The timing of the launch varies from country to country depending on price and reimbursement negotiations with the respective authorities.

GRAZAX is a fast-dissolving, once-daily immunotherapy tablet for home administration. It works by inducing a protective immune response, which reduces and potentially halts the allergic reaction to grass pollen. Treatment with GRAZAX should be initiated at least eight weeks prior to the expected start of the grass pollen season.

The efficacy and safety of GRAZAX have been documented in the largest clinical study programme ever conducted within allergy vaccination. The studies show that 82% of the patients treated with GRAZAX felt 'better' or 'much better' in the first treatment season compared with previous seasons.

ALK-Abelló expects that GRAZAX will primarily be used for patients suffering from moderate to severe allergic rhinitis who are currently not satisfied with their treatment.

For further information please contact:

Jacob Frische,

Director, Communications Manager

Tel: +45 45 74 75 51

Email: jaf@dk.alk-abello.com

Or visit: www.alk-abello.com